Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells

Biochemical Journal

Volumn 417, Issue 2, 2009, Pages 501-511

  Grummer, Mary A ^a   Sullivan, Jeremy A ^a   Magness, Ronald R ^a   Bird, Ian M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Endothelium; Extracellular signal regulated kinase 1 2 (ERK 1 2); Nitric oxide synthase; Pregnancy; Vascular endothelial growth factor receptor 1 (VEGFR 1); VEGFR 2

Indexed keywords

ENDOTHELIUM; EXTRACELLULAR-SIGNAL-REGULATED KINASE 1/2 (ERK-1/2); NITRIC OXIDE SYNTHASE; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (VEGFR-1); VEGFR-2;

ACTIVATION ANALYSIS; BIOACTIVITY; BLOOD VESSEL PROSTHESES; ENZYMES; NITRIC OXIDE; OBSTETRICS; PEPTIDES; PHOSPHORYLATION; SELF ASSEMBLY;

ENDOTHELIAL CELLS;

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; PROTEIN KINASE B; SERINE; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN FUNCTION; SHEEP; SIGNAL TRANSDUCTION; UTERINE ARTERY; ANIMAL; ARTERY; CELL CULTURE; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; UTERUS;

OVIS ARIES;

ANIMALS; ARTERIES; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PREGNANCY; SHEEP; SIGNAL TRANSDUCTION; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 58249085532     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20081013     Document Type: Article

References (49)

1. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J. and Holash, J. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248
2. Reynolds, L. P. and Redmer, D. A. (2001) Angiogenesis in the placenta. Biol. Reprod. 64, 1033-1040
3. Bird, I. M., Zhang, L. and Magness, R. R. (2003) Possible mechanisms underlying pregnancy-induced changes in uterine artery endothelial function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R245-R258
4. Brown, M. A. (1995) The physiology of pre-eclampsia. Clin. Exp. Pharmacol. Physiol. 22, 781-791
5. Hayman, R., Brockelsby, J., Kenny, L. and Baker, P. (1999) Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J. Soc. Gynecol. Investig. 6, 3-10
6. Murakami, Y., Kobayashi, T., Omatsu, K., Suzuki, M., Ohashi, R., Matsuura, T., Sugimura, M. and Kanayama, N. (2005) Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice. Semin. Thromb. Hemost. 31, 307-313
7. Soleymanlou, N., Jurisica, I., Nevo, O., Ietta, F., Zhang, X., Zamudio, S., Post, M. and Caniggia, I. (2005) Molecular evidence of placental hypoxia in preeclampsia. J. Clin. Endocrinol. Metab. 90, 4299-4308
8. Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., Sibai, B. M., Sukhatme, V. P. and Karumanchi, S. A. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683
9. Jelkmann, W. (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 47, 617-623
10. Kou, R., SenBanerjee, S., Jain, M. K. and Michel, T. (2005) Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling. Biochemistry 44, 15064-15073
11. Krysiak, O., Bretschneider, A., Zhong, E., Webb, J., Hopp, H., Verlohren, S., Fuhr, N., Lanowska, M., Nonnenmacher, A., Vetter, R. et al. (2005) Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. Circ. Res. 97, 1253-1261
12. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A. M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605
13. Ahmad, S., Hewett, P. W., Wang, P., Al-Ani, B., Cudmore, M., Fujisawa, T., Haigh, J. J., le Noble, F., Wang, L., Mukhopadhyay, D. and Ahmed, A. (2006) Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ. Res. 99, 715-722
14. Blanes, M. G., Oubaha, M., Rautureau, Y. and Gratton, J. P. (2007) Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells. J. Biol. Chem. 282, 10660-10669
15. 2+, U0126, and wortmannin but not LY294002 - evidence that pregnancy adaptation of eNOS activation occurs at multiple levels of cell signaling. Endocrinology 147, 2442-2457
16. Bird, I. M., Sullivan, J. A., Di, T., Cale, J. M., Zhang, L., Zheng, J. and Magness, R. R. (2000) Pregnancy-dependent changes in cell signaling underlie changes in differential control of vasodilator production in uterine artery endothelial cells. Endocrinology 141, 1107-1117
17. 2. Endocrinology 142, 3014-3026
18. Gifford, S. M., Cale, J. M., Tsoi, S., Magness, R. R. and Bird, I. M. (2003) Pregnancy-specific changes in uterine artery endothelial cell signaling in vivo are both programmed and retained in primary culture. Endocrinology 144, 3639-3650
19. Gifford, S. M., Yi, F. X. and Bird, I. M. (2006) Pregnancy-enhanced store-operated Ca2+ channel function in uterine artery endothelial cells is associated with enhanced agonist-specific transient receptor potential channel 3-inositol 1,4,5-trisphosphate receptor 2 interaction. J. Endocrinol. 190, 385-395
20. 2+ entry rather than altered receptor coupling. J. Endocrinol. 190, 373-384
21. Cale, J. M., Tsoi, S. C., Toppe, M., Grummer, M. A., Ochiai, M., Magness, R. R. and Bird, I. M. (2005) Molecular cloning of ovine endothelial nitric oxide synthase and expression in COS-7 cells. J. Soc. Gynecol. Investig. 12, 156-168
22. Takahashi, T. and Shibuya, M. (1997) The 230 kDa mature form of KDR/ Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14, 2079-2089
23. Nadeau, S., Baribeau, J., Janvier, A. and Perreault, T. (2005) Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr. Res. 58, 199-205
24. Chung, J. Y., Song, Y., Wang, Y., Magness, R. R. and Zheng, J. (2004) Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J. Clin. Endocrinol. Metab. 89, 2484-2490
25. Tsoi, S. C., Wen, Y., Chung, J. Y., Chen, D., Magness, R. R. and Zheng, J. (2002) Co-expression of vascular endothelial growth factor and neuropilin-1 in ovine feto-placental artery endothelial cells. Mol. Cell. Endocrinol. 196, 95-106
26. Cheung, C. Y., Singh, M., Ebaugh, M. J. and Brace, R. A. (1995) Vascular endothelial growth factor gene expression in ovine placenta and fetal membranes. Am. J. Obstet. Gynecol. 173, 753-759
27. Zachary, I. (2003) VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 31, 1171-1177
28. Cale, J. M. and Bird, I. M. (2006) Dissociation of endothelial nitric oxide synthase phosphorylation and activity in uterine artery endothelial cells. Am. J. Physiol. Heart. Circ. Physiol. 290, H1433-H1445
29. Ogawa, S., Oku, A., Sawano, A., Yamaguchi, S., Yazaki, Y. and Shibuya, M. (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273, 31273-31282
30. Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, H. G., Ziche, M., Lanz, C., Buttner, M., Rziha, H. J. and Dehio, C. (1999) A novel vascular endothelial growth factor encoded by orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (flt-1) receptor tyrosine kinases. EMBO J. 18, 363-374
31. Cudmore, M., Ahmad, S., Al-Ani, B., Hewett, P., Ahmed, S. and Ahmed, A. (2006) VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem. Biophys. Res. Commun. 345, 1275-1282
32. Bausero, P., Cavaille, F., Meduri, G., Freitas, S. and Perrot-Applanat, M. (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2, 167-182
33. Wheeler, T., Evans, P. W., Anthony, F. W., Godfrey, K. M., Howe, D. T. and Osmond, C. (1999) Relationship between maternal serum vascular endothelial growth factor concentration in early pregnancy and fetal and placental growth. Hum. Reprod. 14, 1619-1623
34. Vonnahme, K. A., Wilson, M. E., Li, Y., Rupnow, H. L., Phernetton, T. M., Ford, S. P. and Magness, R. R. (2005) Circulating levels of nitric oxide and vascular endothelial growth factor throughout ovine pregnancy. J. Physiol. 565, 101-109
35. Magness, R. R. (1998) Maternal cardiovascular and other physiologic responses to the endocrinology of pregnancy. In Endocrinology of Pregnancy (Bazer, F., ed.), pp. 507-539, Humana Press, Totowa, NJ
36. Sugino, N., Kashida, S., Karube-Harada, A., Takiguchi, S. and Kato, H. (2002) Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy. Reproduction 123, 379-387
37. Polliotti, B. M., Fry, A. G., Saller, D. N., Mooney, R. A., Cox, C. and Miller, R. K. (2003) Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet. Gynecol. 101, 1266-1274
38. Nevo, O., Soleymanlou, N., Wu, Y., Xu, J., Kingdom, J., Many, A., Zamudio, S. and Caniggia, I. (2006) Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R1085-R1093
39. Cale, J. M. and Bird, I. M. (2006) Inhibition of MEK/ERK1/2 signalling alters endothelial nitric oxide synthase activity in an agonist-dependent manner. Biochem. J. 398, 279-288
40. Rahimi, N. (2006) Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp. Eye Res. 83, 1005-1016
41. Rosado, J. A. and Sage, S. O. (2000) Phosphoinositides are required for store-mediated calcium entry in human platelets. J. Biol. Chem. 275, 9110-9113
42. Chen, X. and Wang, Z. (2001) Regulation of epidermal growth factor receptor endocytosis by wortmannin through activation of Rab5 rather than inhibition of phosphatidylinositol 3-kinase. EMBO Rep. 2, 842-849
43. Warashina, A. (2001) Mechanism by which wortmannin and LY294002 inhibit catecholamine secretion in the rat adrenal medullary cells. Cell Calcium 29, 239-247
44. Jandu, N., Shen, S., Wickham, M. E., Prajapati, R., Finlay, B. B., Karmali, M. A. and Sherman, P. M. (2007) Multiple seropathotypes of verotoxin-producing Escherichia coli (VTEC) disrupt interferon-gamma-induced tyrosine phosphorylation of signal transducer and activator of transcription (stat)-1. Microb. Pathog. 42, 62-71
45. Jenner, S., Farndale, R. W. and Sage, S. O. (1996) Wortmannin inhibits store-mediated calcium entry and protein tyrosine phosphorylation in human platelets. FEBS Lett. 381, 249-251
46. Cross, M. J., Stewart, A., Hodgkin, M. N., Kerr, D. J. and Wakelam, M. J. (1995) Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J. Biol. Chem. 270, 25352-25355
47. Arcaro, A., Volinia, S., Zvelebil, M. J., Stein, R., Watton, S. J., Layton, M. J., Gout, I., Ahmadi, K., Downward, J. and Waterfield, M. D. (1998) Human phosphoinositide 3-kinase C2β, the role of calcium and the C2 domain in enzyme activity. J. Biol. Chem. 273, 33082-33090
48. Maffucci, T., Cooke, F. T., Foster, F. M., Traer, C. J., Fry, M. J. and Falasca, M. (2005) Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J. Cell Biol. 169, 789-799
49. Arcaro, A., Zvelebil, M. J., Wallasch, C., Ullrich, A., Waterfield, M. D. and Domin, J. (2000) Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol. Cell. Biol. 20, 3817-3830